A study conducted by Mount Sinai has found that pharmaceutical advertisements can influence treatment recommendations provided by artificial intelligence systems. As AI tools are increasingly integrated into healthcare and information environments, this finding highlights potential vulnerabilities in how these technologies process and reflect promotional material when generating medical guidance. The research sheds light on the interplay between commercial drug advertising and AI-driven clinical decision support, pointing to important considerations for developers, regulators, and medical professionals who rely on artificial intelligence technologies.